Malignancy-Associated Thrombosis

References

• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.
   PubMed Web of Science ®Google Scholar
• Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995;92(18):8205–9.
   PubMed Web of Science ®Google Scholar
• Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992;89(24):11832–6.
   PubMed Web of Science ®Google Scholar
• Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A. 2001;98(14):7742–7.
   PubMed Web of Science ®Google Scholar
• Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 2004;23(2):410–7.
   Web of Science ®Google Scholar
• Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734–41.
   PubMed Web of Science ®Google Scholar
• Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. The Oncologist. 1999;4(6):443–9.
   PubMedGoogle Scholar
• Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost. 2007;5(3):520–7.
   PubMed Web of Science ®Google Scholar
• Zurborn KH, Gram J, Glander K, et al. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias. Eur J Haematol. 1991;47(1):55–9.
   Web of Science ®Google Scholar
• Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–21.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 2003;98(6):1239–42.
   PubMed Web of Science ®Google Scholar
• Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: A single-centre analysis. Brit J Cancer. 2005;92(8):1349–51.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2006;47(6):1029–33.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. JNCI. 2006;98(10):708–14.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–90.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000;160(6):809–15.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822–9.
   PubMed Web of Science ®Google Scholar
• Cantwell BM, Carmichael J, Ghani SE, Harris AL. Thromboses and thromboemboli in patients with lymphoma during cytotoxic chemotherapy. BMJ (Clinical research ed.) 1988;297(6642):179–80.
   Google Scholar
• Clarke CS, Otridge BW, Carney DN. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer. 1990;66(9):2027–30.
   Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8.
   PubMed Web of Science ®Google Scholar
• Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol. 2000;18(17):3078–83.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Piccioli A, Pagnan A. Recurrent thromboembolism in cancer patients: Incidence and risk factors. Seminars in Thrombosis and Hemostasis. 2003;29 Suppl 1:3–8.
   Google Scholar
• Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. The Lancet Oncology. 2005;6(6):401–10.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med. 2004;140(11):867–73.
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695–702.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–76.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA. 2006;295(13):1519–30.
   PubMed Web of Science ®Google Scholar
• Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409–15.
   PubMed Web of Science ®Google Scholar
• Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653–61.
   PubMedGoogle Scholar
• Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23(18):4057–62.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Moia M, Falanga A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study. Brit J Haematology. 2005;129(6):811–7.
   PubMed Web of Science ®Google Scholar
• Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23(18):4063–9.
   PubMed Web of Science ®Google Scholar
• Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006;17(2):289–96.
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–9.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944–8.
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130–5.
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2(8):1266–71.
   PubMed Web of Science ®Google Scholar
• Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane database of systematic reviews. (Online) 2007(3):CD006652.
   Web of Science ®Google Scholar